OR Royalties Inc. (OR) to Issue Quarterly Dividend of $0.07 on July 15th

OR Royalties Inc. (NYSE:OR) announced a quarterly dividend on Wednesday, May 6th. Stockholders of record on Tuesday, June 30th will be given a dividend of 0.065 per share by the basic materials company on Wednesday, July 15th. This represents a c) dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, June 30th. This is a 18.2% increase from OR Royalties’s previous quarterly dividend of $0.06.

OR Royalties has raised its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 1 years. OR Royalties has a payout ratio of 33.3% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect OR Royalties to earn $1.51 per share next year, which means the company should continue to be able to cover its $0.25 annual dividend with an expected future payout ratio of 16.6%.

OR Royalties Stock Performance

NYSE:OR opened at $32.26 on Friday. The company has a 50-day moving average of $36.48 and a 200-day moving average of $38.70. The company has a market capitalization of $6.05 billion, a price-to-earnings ratio of 24.08 and a beta of 0.70. OR Royalties has a 52 week low of $24.79 and a 52 week high of $48.06.

OR Royalties (NYSE:OR) last released its quarterly earnings data on Wednesday, May 6th. The basic materials company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. The company had revenue of $102.83 million for the quarter, compared to analyst estimates of $103.27 million. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%. Sell-side analysts forecast that OR Royalties will post 1.4 EPS for the current year.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.